Biological study of the effect of GW572016 (Lapatinib) in cell apoptosis in ductal carcinoma in situ in patients with HER2-positive breast cancer

Trial Profile

Biological study of the effect of GW572016 (Lapatinib) in cell apoptosis in ductal carcinoma in situ in patients with HER2-positive breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2012

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 04 May 2012 Status changed from recruiting to completed, according to the European Clinical Trials Database.
    • 23 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top